ES
Egbert Smit
Leiden University Medical Center
Research areas: Medicine · Pulmonary and Respiratory Medicine · Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment · Lung Cancer Research Studies
0000-0002-7329-6995
Employment
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (571)
- Validation of a Text-Mining Tool for Extracting Routine Clinical Care Data in Early-Stage Resectable Non–Small Cell Lung Cancer Save
- Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer Save
- Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better? Save
- Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review Save
- Impact of CMV Infection and Cancer Treatment on Vaccine Efficacy in Oncology Patients Save
- Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis Save
- Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials Save
- Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02 Save
- Data from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Figure S1. Accrual and follow-up1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S1. Response associations1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S2. First progression sites2 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S3. Met alterations3 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S4. Differential expression4 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S5. Other crizotinib trials5 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S6. Other c-MET-inhibitors6 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Table S7. Representativeness7 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Save
- Data from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Save
- Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Save